Invesco’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.18B Buy
3,454,585
+443,580
+15% +$450M 0.31% 47
2025
Q4
$3.24B Sell
3,011,005
-27,936
-0.9% -$26.7M 0.31% 47
2025
Q3
$2.32B Sell
3,038,941
-191,138
-6% -$142M 0.37% 32
2025
Q2
$2.52B Sell
3,230,079
-1,928
-0.1% -$1.5M 0.43% 24
2025
Q1
$2.67B Sell
3,232,007
-440,808
-12% -$367M 0.51% 18
2024
Q4
$2.84B Sell
3,672,815
-7,993
-0.2% -$6.62M 0.52% 15
2024
Q3
$3.26B Buy
3,680,808
+392,666
+12% +$353M 0.63% 9
2024
Q2
$2.98B Buy
3,288,142
+138,821
+4% +$111M 0.63% 9
2024
Q1
$2.45B Buy
3,149,321
+82,149
+3% +$58.5M 0.53% 13
2023
Q4
$1.79B Sell
3,067,172
-190,873
-6% -$111M 0.43% 24
2023
Q3
$1.75B Sell
3,258,045
-697,608
-18% -$359M 0.47% 21
2023
Q2
$1.86B Sell
3,955,653
-73,484
-2% -$30.8M 0.49% 18
2023
Q1
$1.38B Sell
4,029,137
-109,689
-3% -$37M 0.39% 31
2022
Q4
$1.51B Sell
4,138,826
-717,500
-15% -$254M 0.44% 20
2022
Q3
$1.57B Buy
4,856,326
+57,969
+1% +$18.4M 0.51% 16
2022
Q2
$1.56B Buy
4,798,357
+6,419
+0.1% +$1.93M 0.47% 20
2022
Q1
$1.37B Sell
4,791,938
-482,716
-9% -$124M 0.35% 39
2021
Q4
$1.46B Buy
5,274,654
+242,241
+5% +$61.4M 0.35% 42
2021
Q3
$1.16B Sell
5,032,413
-707,723
-12% -$175M 0.29% 52
2021
Q2
$1.32B Sell
5,740,136
-335,617
-6% -$67.4M 0.32% 40
2021
Q1
$1.14B Sell
6,075,753
-384,766
-6% -$75.3M 0.3% 44
2020
Q4
$1.09B Buy
6,460,519
+1,907,345
+42% +$285M 0.32% 43
2020
Q3
$674M Sell
4,553,174
-291,280
-6% -$45.1M 0.23% 83
2020
Q2
$795M Sell
4,844,454
-615,095
-11% -$94.4M 0.28% 63
2020
Q1
$757M Buy
5,459,549
+317,893
+6% +$43.7M 0.32% 54
2019
Q4
$676M Buy
5,141,656
+422,989
+9% +$49M 0.21% 103
2019
Q3
$528M Sell
4,718,667
-343,361
-7% -$38.2M 0.14% 163
2019
Q2
$561M Sell
5,062,028
-312,967
-6% -$36.9M 0.14% 149
2019
Q1
$697M Sell
5,374,995
-1,328,740
-20% -$162M 0.24% 85
2018
Q4
$776M Sell
6,703,735
-974,285
-13% -$109M 0.3% 69
2018
Q3
$824M Sell
7,678,020
-326,682
-4% -$32.7M 0.26% 73
2018
Q2
$683M Buy
8,004,702
+1,025,891
+15% +$84.3M 0.23% 93
2018
Q1
$540M Sell
6,978,811
-93,894
-1% -$7.56M 0.2% 116
2017
Q4
$597M Buy
7,072,705
+276,051
+4% +$23.5M 0.22% 101
2017
Q3
$581M Sell
6,796,654
-669,966
-9% -$54.9M 0.21% 104
2017
Q2
$615M Sell
7,466,620
-556,576
-7% -$45.4M 0.19% 111
2017
Q1
$675M Sell
8,023,196
-2,541,851
-24% -$204M 0.22% 89
2016
Q4
$777M Buy
10,565,047
+791,684
+8% +$59M 0.26% 73
2016
Q3
$784M Sell
9,773,363
-771,769
-7% -$61.8M 0.27% 69
2016
Q2
$830M Buy
10,545,132
+180,293
+2% +$13.6M 0.31% 65
2016
Q1
$746M Sell
10,364,839
-1,258,522
-11% -$95.2M 0.3% 61
2015
Q4
$979M Buy
11,623,361
+2,202,646
+23% +$183M 0.39% 42
2015
Q3
$788M Sell
9,420,715
-2,291,177
-20% -$193M 0.33% 49
2015
Q2
$978M Buy
11,711,892
+1,265,562
+12% +$96.4M 0.38% 37
2015
Q1
$759M Sell
10,446,330
-672,306
-6% -$47.9M 0.29% 66
2014
Q4
$767M Buy
11,118,636
+826,479
+8% +$55.8M 0.3% 57
2014
Q3
$667M Sell
10,292,157
-814,854
-7% -$51.6M 0.27% 71
2014
Q2
$691M Buy
11,107,011
+964,995
+10% +$57.6M 0.27% 65
2014
Q1
$597M Buy
10,142,016
+466,737
+5% +$26M 0.24% 80
2013
Q4
$493M Sell
9,675,279
-1,776,773
-16% -$89M 0.2% 101
2013
Q3
$576M Sell
11,452,052
-1,469,717
-11% -$76.9M 0.25% 74
2013
Q2
$635M Buy
+12,921,769
New +$703M 0.3% 70

Other funds holding LLY

Invesco's LLY Position: Q1 2026 in Review

Invesco increased its Eli Lilly (LLY) stake by 15% in Q1 2026, buying an estimated $450M and bringing the position to 3,454,585 shares worth $3.18B. The position accounts for 0.31% of the portfolio, ranked #47.

Invesco first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.26B in Q3 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Invesco held 3,454,585 shares of Eli Lilly worth $3.18B as of Q1 2026.
  • Invesco bought 443,580 Eli Lilly shares in Q1 2026, an estimated $450M.
  • Eli Lilly made up 0.31% of Invesco's portfolio in Q1 2026, its #47 holding.
  • Invesco first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Invesco's Eli Lilly position peaked at $3.26B in Q3 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.